Razoxane in the treatment of psoriatic patients resistant to or intolerant of PUVA, methotrexate and etretinate.
Thirty-six psoriatic patients resistant to or intolerant to PUVA, methotrexate and/or etretinate were treated with razoxane (ICRF 159) and EDTA derivative with antimitotic effects. The drug is highly effective in cutaneous and arthropathic psoriasis. Razoxane is well tolerated and appears to be free of hepatotoxicity. Besides some nausea and lethargy, 60% of the patients showed neutropenia, which can be easily controlled.
D000328:Adult; D000368:Aged; D004351:Drug Resistance; D005050:Etretinate / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D011701:PUVA Therapy; D010879:Piperazines / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy*; D011929:Razoxane / Q000627:therapeutic use*
D010879:Piperazines; D011929:Razoxane; D005050:Etretinate; D008727:Methotrexate